These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19621390)

  • 21. A highly sensitive prenylation assay reveals in vivo effects of bisphosphonate drug on the Rab prenylome of macrophages outside the skeleton.
    Ali N; Jurczyluk J; Shay G; Tnimov Z; Alexandrov K; Munoz MA; Skinner OP; Pavlos NJ; Rogers MJ
    Small GTPases; 2015 Oct; 6(4):202-11. PubMed ID: 26399387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells.
    Chang JW; Hsieh JJ; Shen YC; Yeh KY; Wang CH; Li YY; Hsu T
    Cancer Lett; 2009 Jun; 278(1):17-26. PubMed ID: 19233551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice.
    Ory B; Heymann MF; Kamijo A; Gouin F; Heymann D; Redini F
    Cancer; 2005 Dec; 104(11):2522-9. PubMed ID: 16270320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regression of a primary pulmonary adenocarcinoma after zoledronic acid monotherapy.
    Nagao S; Hattori N; Fujitaka K; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Haruta Y; Murai H; Kohno N
    Hiroshima J Med Sci; 2011 Mar; 60(1):7-9. PubMed ID: 21675041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bisphosphonates: preclinical review.
    Green JR
    Oncologist; 2004; 9 Suppl 4():3-13. PubMed ID: 15459425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer.
    Tardoski S; Ngo J; Gineyts E; Roux JP; Clézardin P; Melodelima D
    Sci Rep; 2015 Nov; 5():16354. PubMed ID: 26578234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer.
    Søe K; Delaissé JM; Jakobsen EH; Hansen CT; Plesner T
    Acta Oncol; 2014 Apr; 53(4):547-56. PubMed ID: 24164102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.
    Bruzzese F; Pucci B; Milone MR; Ciardiello C; Franco R; Chianese MI; Rocco M; Di Gennaro E; Leone A; Luciano A; Arra C; Santini D; Caraglia M; Budillon A
    Cell Death Dis; 2013 Oct; 4(10):e878. PubMed ID: 24157872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
    Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M
    J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
    Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
    Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro.
    Räikkönen J; Crockett JC; Rogers MJ; Mönkkönen H; Auriola S; Mönkkönen J
    Br J Pharmacol; 2009 Jun; 157(3):427-35. PubMed ID: 19371349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.
    Baulch-Brown C; Molloy TJ; Yeh SL; Ma D; Spencer A
    Leuk Res; 2007 Mar; 31(3):341-52. PubMed ID: 16996129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid.
    Lamoureux F; Ory B; Battaglia S; Pilet P; Heymann MF; Gouin F; Duteille F; Heymann D; Redini F
    Int J Cancer; 2008 Feb; 122(4):751-60. PubMed ID: 17960623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
    Ottewell PD; Woodward JK; Lefley DV; Evans CA; Coleman RE; Holen I
    Mol Cancer Ther; 2009 Oct; 8(10):2821-32. PubMed ID: 19789217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?
    Morgan GJ
    Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S24-30. PubMed ID: 21353177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor effects of bisphosphonates.
    Green JR
    Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular mechanisms of action of bisphosphonates: current status.
    Roelofs AJ; Thompson K; Gordon S; Rogers MJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
    Rogers TL; Wind N; Hughes R; Nutter F; Brown HK; Vasiliadou I; Ottewell PD; Holen I
    Cell Oncol (Dordr); 2013 Dec; 36(6):505-14. PubMed ID: 24177992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.
    Ohba T; Cole HA; Cates JM; Slosky DA; Haro H; Ando T; Schwartz HS; Schoenecker JG
    J Bone Miner Res; 2014 Jun; 29(6):1431-45. PubMed ID: 24443409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.